Celebrity Inventors
Penn Jillette of Penn and Teller fame has patented a "Hydro-Therapeutic Stimulator", which uses a hot tub for stimulation.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128771 | TIMED, PULSATILE RELEASE SYSTEMS A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug partic... | 05/24/2012 |
| 20110311626 | CONTROLLED RELEASE COMPOSITIONS COMPRISING ANTI-CHOLINERGIC DRUGS The present invention provides compositions comprising dicyclomine, or salts, and/or solvates and methods of making and using the compositions to treat intestinal hypermotility or Irritable Bowel Syndrome (IBS). The present invention also provides once-a-day orally disi... | 12/22/2011 |
| 20110300217 | HYDROMORPHONE THERAPY A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.... | 12/08/2011 |
| 20110300209 | MODIFIED RELEASE SOLID PHARMACEUTICAL COMPOSITIONS OF TRIMETAZIDINE AND PROCESS THEREOF There is provided a modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.... | 12/08/2011 |
| 20110293718 | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.... | 12/01/2011 |
| 20110287097 | PHARMACEUTICAL COMPOSITIONS COMPRISING ROPINIROLE Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate for... | 11/24/2011 |
| 20110287099 | Sustained-release formulations of topiramate Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to releas... | 11/24/2011 |
| 20110287100 | Galenic Formulations of Organic Compounds A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount of aliskiren and the outer coating is in the form of a film-coat with tast... | 11/24/2011 |
| 20110287095 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules ... | 11/24/2011 |
| 20110287101 | RAPID RELEASE MINI-TABLETS PROVIDE ANALGESIA IN LABORATORY ANIMALS Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after ... | 11/24/2011 |
| 20110280923 | BOLUS DEVICES FOR THE DELIVERY OF ACTIVE AGENTS TO ANIMALS A bolus for administration of a substance to an animal, the bolus including An external coating, and A core inside the external coating wherein the core is formed from a plurality of dosage media, wherein each dosage media contains a substance, the bolus characterised i... | 11/17/2011 |
| 20110274754 | ORAL TABLET COMPOSITIONS OF DEXLANSOPRAZOLE Oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof having a gradual release and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.... | 11/10/2011 |
| 20110268795 | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is i... | 11/03/2011 |
| 20110244034 | SUSTAINED RELEASE DRUG DELIVERY SYSTEM The invention discloses a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, illustrated by Acyclovir, that would release in about 12 hours not more than about 90% of the said active agent in a simulated gast... | 10/06/2011 |
| 20110223247 | PHARMACEUTICAL COMPOSITIONS FOR RELEASE CONTROL OF METHYLPHENIDATE Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material containing methylphenidate and a polymer coating layer for release control form... | 09/15/2011 |
| 20110217374 | PHARMACEUTICAL COMPOSITION SIMULTANEOUSLY HAVING RAPID-ACTING PROPERTY AND LONG-ACTING PROPERTY Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least on... | 09/08/2011 |
| 20110212174 | CONTROLLED RELEASE ARGININE FORMULATIONS A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 1A shows a schematic representation of proposed L-arginine dependent and independent pathways.... | 09/01/2011 |
| 20110212173 | Controlled Release Treatment of Depression There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, tri... | 09/01/2011 |
| 20110207823 | 12-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 15 mg drug substance tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a h... | 08/25/2011 |
| 20110200671 | METHOD OF TREATING A DISEASE CONDITION SUSCEPTIBLE TO BACLOFEN THERAPY The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptab... | 08/18/2011 |
| 20110195122 | Extended Release Formulation The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.... | 08/11/2011 |
| 20110195121 | CHRONOTHERAPEUTIC PHARMACEUTICAL DOSAGE FORM This invention relates to a pharmaceutical dosage form for the phase-controlled and chronotherapeutic delivery of at least one and, preferably, several pharmaceutically active ingredients. The dosage form has a carrier platform which,—preferably, is a polymer having k... | 08/11/2011 |
| 20110195120 | Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride A monolithic sustained-release pharmaceutical composition comprising a therapeutically effective dose of metformin hydrochloride as an active substance and a hydrophobic polymer and/or other hydrophobic material, wherein the metformin hydrochloride is released no more t... | 08/11/2011 |
| 20110177164 | Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof A stabilized pharmaceutical composition of benzimidazole compounds preferably amorphous form of esomeprazole and a process for preparing the same. The pharmaceutical compositions formulated into solid dosage forms preferably multiple unit tablet dosage forms and capsule... | 07/21/2011 |
| 20110159088 | ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS The field of the present invention is that of oral pharmaceutical forms of at least one active principle AP whose solubility varies greatly as a function of the gastric pH, and also treatments and administration methods relating thereto. Th... | 06/30/2011 |
| 20110150994 | Modified Release Formulation The invention is directed to the use of an extended release tablet formulation for pramipexole.... | 06/23/2011 |
| 20110150989 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules ... | 06/23/2011 |
| 20110142932 | Pharmaceutical Tablets Comprising a Plurality of Segments Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.... | 06/16/2011 |
| 20110142905 | COATED TABLETS WITH REMAINING DEGRADATION SURFACE OVER THE TIME The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet, preferably obtainable by compression, said tablet comprising said at leas... | 06/16/2011 |
| 20110123618 | Controlled release formulation of lamotrigine Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventio... | 05/26/2011 |
| 20110111022 | PHARMACEUTICAL FORMULATION The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the ... | 05/12/2011 |
| 20110104269 | COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestin... | 05/05/2011 |
| 20110091548 | USE OF A MATRIX FOR ORALLY ADMINISTERING SUSTAINED RELEASE MAGNESIUM, AND COMPOSITION CONTAINING SAID MATRIX A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by... | 04/21/2011 |
| 20110081412 | ORALLY DISINTEGRABLE TABLETS An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more... | 04/07/2011 |
| 20110070304 | MANUFACTURE OF TABLET HAVING IMMEDIATE RELEASE REGION AND SUSTAINED RELEASE REGION In one aspect, the present invention features a process for making a tablet including a pharmaceutically active agent wherein the tablet has both an immediate release region and a modified release region. The method includes the steps of: (a) forming a tablet shape incl... | 03/24/2011 |
| 20110070303 | NOVEL DOSAGE FORMULATION The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I wherein the definitions are described in claim 1, o... | 03/24/2011 |
| 20110064803 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2 The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in th... | 03/17/2011 |
| 20110059169 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... | 03/10/2011 |
| 20110052683 | PHARMACEUTICAL PREPARATION FOR TREATING CARDIOVASCULAR DISEASE The present invention provides a pharmaceutical preparation comprising a prior-release compartment containing a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor as a pharmacologically active ingredient, and a delayed-release compartment containing a non-dihydropy... | 03/03/2011 |
| 20110052686 | MODIFIED RELEASE LAMOTRIGINE TABLETS The present invention relates to uncoated modified-release tablets of lamotrigine and the process for preparation thereof, wherein the tablets comprise a portion of lamotrigine in an admixture with a pH-dependent polymer.... | 03/03/2011 |
